Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Metastatic
BRCA 1 Gene Mutation
BRCA 2 Gene Mutation

Interventions

DRUG: Olaparib
DRUG: Physician's choice chemotherapy

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]